Difficult AirwayNCT04618926
A Comparison of Fiberoptic Endotracheal Intubation Between the Intubating Laryngeal Tube Suction and the LMA Protector
An observational study of Difficult Airway, run by Bnai Zion Medical Center.
Trial summary
Securing the airway is a pivotal skill for anesthesiologists and emergency care providers. Endotracheal intubation (ETI) is considered the gold standard for securing the airway. When ETI via laryngoscopy has failed, the use of a supraglottic airway device (SGAD) has been recommended. Read more about this study
- Who is it for?
- Ages 18 to 75 years
- Conditions the study is for
- Difficult Airway
- What is being tested?
- Device intubating Laryngeal Tube Suction Disposable
- Type of treatment
- Medical device
- How many people
- 80 participants
- Where
- No sites listed yet
- Study dates
- 1 Apr 2021to 31 Dec 2021
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 75 years
- All sexes
- No healthy volunteers
- Adult, Older adult
Study population: We will recruit patients if they are ≥18 years of age and of American Society of Anesthesiologists (ASA) physical status 1-2
Who may be able to join
- Patients with normal airway
- weight 50-90kg
- AGE 18-75
- ASA I-II
Who cannot join
- predicted difficult airway
- weight > 90 Kg
- aspiration risk
- pregnancy woman.
Trial locations and contacts
No sites are listed yet.
About this study
Official title: A Prospective Randomized Study Comparing Fiberoptic Bronchoscope Endotracheal Intubation Between the Intubating Laryngeal Tube Suction and the LMA Protector
Securing the airway is a pivotal skill for anesthesiologists and emergency care providers. Endotracheal intubation (ETI) is considered the gold standard for securing the airway.
When ETI via laryngoscopy has failed, the use of a supraglottic airway device (SGAD) has been recommended. The intubating Laryngeal Tube Suction-Disposable and the LMA Protector are a new step in the evolution of supraglottic airways. Both SGADs are enable to ventilation and oxygenation, but the ventilation channel allow the insertion of an endotracheal tube and the use of fiberoptic bronchoscope. The aim of this study is to compare the time of fiberoptic intubation through the intubating Laryngeal Tube Suction Disposable and the LMA Protector in adult patients.
Read the detailed description
Detailed Description: Securing the airway is a pivotal skill for anesthesiologist and emergency providers. Endotracheal intubation (ETI) is considered the gold standard for securing the airway. Induction time during anesthesia may sometimes present unexpected difficulties during ETI.
When ETI via laryngoscopy has failed, the use of a supraglottic airway device (SGAD) has been recommended. Previous studies suggested that compare intubation with laryngoscope, SGADs enables rapid and effective airway control. Improved second generation SGADs enable ventilation and oxygenation, but also include a second channel that separates the trachea from the esophagus preventing aspiration. According with the results of the Fourth National Audit Project of the Royal College of Anesthetist will bets and the Difficult Airway Society, the second generation SGADs should be uses instead the first generation.
Some of the second generations of SGADs have a ventilation channel that allow the insertion of an endotracheal tube.
Two of these devices recently introduced in the market are the intubating Laryngeal Tube Suction Disposable (iLTS-D) and the Laryngeal Mask Airway Protector [5, 6] The intubating Laryngeal Tube Suction- Disposable (iLTS-D) (VBM, Germany) is a new updated version of the Laryngeal Tube-Suction Disposable (LTS-D). [5] It has a ventilator channel with a 13.5mm internal diameter, which enables the passage of an Endotracheal Tube (ETT) No 7.5 mm. for fiberoptic guidance. Similarly to the LTS-D, the iLTS-D also has a separate channel for gastric tubes placement up to a size of 18 Fr. The device is latex free, made of PVC, and like the original laryngeal tube (LT), can be inserted blindly.
The iLTS-D comes in one size. According to the depth of insertion, the device will be equivalent to size 4 for patients 175 to 190 cm tall, or size 5 for patients taller than 190 cm.
The LMA Protector™ Airway (Teleflex Ireland) will be a new step in the evolution of supraglottic airways. This is a single use device made mainly of silicone. The LMA Protector is designed to provide an opportunity to insert a tracheal tube of proper size through the device without the need of any special technique. [6] It is a PVC, double- lumen tube. One lumen will be used for ventilation and the others for gastric tube placement.
The ventilation channel has the ability to pass an ETT 7.5 mm with a fiberscope. The LMA Protector will be provide in sizes from 3, 4 and 5. The size 3 will be for patient of weight 30 to 50 Kg, the size 4 to patients of weight from 50 to 70 Kg and the size 5 to patients of weight 70 to 100 Kg.
Unlike the most of the second generation SGAD the LMA Protector possesses a shortand wide-bore preformed airway tube. Thwill be allows passage of wide internal diameter ETTs. It will be currently one of the few second-generation .SADs together with the iLTS-D that can also act as a conduit for endotracheal intubation.
The two SGDs will be inserted blindly with its distal tip positioned in the upper esophagus.
The aim of this be study will be to compare the time of fiberoptic intubation through the intubating Laryngeal Tube Suction Disposable and the LMA Protector in adult patients. The procedures will be performed by anesthesiologist with no previous experience with these two devices.
We hypothesized that the time needed for first-attempt successful fiberoptic-guided intubation with the two novel SADs would not differ by more than 10 s.
MATERIALS AND METHODS The study will obtain the approval of the Bnai Zion Medical Center Clinical Research Ethics Committee and will be obtain the registration from the ClinicalTrials.gov We will recruit patients if they have ≥18 years of age and of American Society of Anesthesiologic (ASA) physical status 1-2. Exclusion criteria included patients who have predicted to a difficult airway, who has any contraindication to the use of an SAD, weight > 90 Kg, aspiration risk and pregnancy woman.
After written informed consent , patients will be assigned, using a computer-generated randomized list, to having their airway intubated fibreopticaly through either an LMA Protector or iLTS-D. Patients will be blinded as to their allocation group.
The intubation will be performed by two experienced anesthesiologist, defined as having more than 10 years of clinical experience since the commencement of specialty and expert with Supraglottic Devices and fiberscope intubation.
All anesthesiologist involved in this study will participate in a standardized educational program and practice on an airway manikin and patients. Anesthesiologist will completed >10 uses on each device prior to the study either in simulators and patients.
The size of the LMA Protector was chosen by the intubating anesthesiologist based on the patient's weight and airway assessment. Size 3 to patient weighs of 30 to 50 Kg and size 4 to patient weight of 50 to 70 Kg. and 5 to patient weight of 70 to 100 Kg. The iLTS-D has only one size with marks in the proximal end of the device with the number 4 or 5 in order to guide the insertion more deep or more superficial according with the height of the patients. Number 4, color red, to adult height of 155-180 cm and number 5, color purple, to adult height of > 180 cm.
For each participant the following data will be recorded preoperatively: age, sex, height, weight, ASA physical status, predictors for difficult airway (Mallampati score, thyromental distance), and type of surgery.
After 3 minutes of pre-oxygenation with 100% oxygen to reach an end-tidal O2 ≥70 %, patients will be given induction agents.
Anesthesia will be induced with up to 2-3 mg/kg propofol, 3mcg/kg fentanyl and maintained with 70% nitrous oxide/30% oxygen and sevofluorane. Neuromuscular blockade will be obtained with rocuronium bromide 0.6 mg/kg.
After complete muscle paralysis (train of four = 0), the allocated SAD will be inserted by the study anesthesiologist according to the manufacturer's instructions.
The time to effective SGAD insertion will be define by the time between the devices was in the level of the lip patients until the CO2 waveform will be observed on the monitor display.
When more than one insertion attempt will be require, the patient will be receive bag-and-mask ventilation between attempts. A fail insertion attempt will be defined as complete withdrawal of the device from the mouth following an unsuccessful placement.
After two attempts the device will be deemed to have fail and the study protocol will be stop.The treating anesthetesiologist will then proceeded with the airway management of their choosing according to the needs of the patient and the surgery.
After achieving satisfactory ventilation via the allocated SAD, fibreoptic-guided tracheal intubation will be start.
A fiberscope (Karl Storz, Tuttlingen, Germany) with an outer diameter of 4.8 mm was used in all fiberoptic-guided procedures. All intubations will be perform with a disposable Endotracheal Tube with a low pressure, high volume cuff (VBM Medizintechnik GmbH, Sulz, Germany) with an internal diameter of 7.5 mm.
The flexible fiberscope will be loaded with the tracheal tube (TT), and advanced 2 cm beyond the TT for guidance. The participant will advance the fiberscope to the end of the SAD and the glottis will be view and assessed.
The scope will be insert into the trachea, the ETT will be railroad into the trachea, and the fibrescope will be then remove. Proper placement of the ETT will be confirm clinically and by the presence of the end tidal CO2 trace. The SAD will be then removed according to the manufacturer's instructions. After this maneuver the position of the ETT relative to the carina will be assessed bronchoscopicaly.
A maximum of two attempts will be s allowed with fibreoptic guided intubation. An alternative airway management plan could be instituted at the criterion by the anesthesiologist if a failed intubation is encountered after two attempts with the allocated device. The time of fiberscope intubation will be defined how the time when the fiberoscope is inserted in the ventilation channel of the SGAD until the presence of the CO2 waveform trace in the display of the monitor.
The primary outcome variable will be the total time to achieve successful fibreoptic intubation through the SADs (time to insertion of the SAD plus time to fibreoptic TI). Secondary variables included the following: SAD insertion time; TT insertion time; intubation success rate, and glottic view according to the Fiber-Optic Scoring System proposed by Brimacombe et al. In order to standardize the assessment of the SGD position (4 = only vocal cords seen; 3 = vocal cords plus posterior epiglottwill be seen; 2 = vocal cords plus anterior epiglottis seen; 1= vocal cords not seen), maneuvers performed to achieve TI (up-down mobilization or side to side mobilization) and Likert scale.
The anesthesiologist will be asked to rate the ease of use of the fiberscope-guided technique on a Likert scale for each technique, using the statement: ''The TT was easily inserted into the trachea'' (1 = strongly agree, 2 = disagree, 3 = neither agree nor disagree, 4 = agree, 5 = strongly agree) (8).
Statistical analysis will be performed. The primary outcome will be time to fiberoptic-guided TI. Based on the pilot study, the investigator expected to obtain a large Cohen's d effect size corresponding to a time difference of at least 10 s, relative to the observed standard deviations (SDs) (9). In order to achieve a statistical significance for such mean time differences when using a repeated-measures procedure with an overall significance level of 0.05 (a = 0.05/3 for each pair with the Bonferroni adjustment) and a power of 0.8, a sample size of 24 would be necessary. The statistical power was calculated using G*Power free, version 3.0.10 (Franz Faul, University of Kiel, Kiel, Germany). A repeated-measures model was used to compare the mean time measurements (SAD insertion time, time to TI, and total time to secure the airway using fiberscope intubation technique among the two devices.
Categorical data were analyzed with nonparametric Friedman's two-way analysis of variance test. If the results were statistically significant at a 5% significance level, the tests were followed by post-hoc multiple compare between each pair of study devices. The paired t-test was used to analyze continuous data, and the Sign test was used to compare two dependent samples of categorical data sets.
According to Bonferroni multiple comparison adjustments, when comparing each pair of devices, p values <0.017 were considered statistical significant. SPSS, version 20 (SPSS Inc., IBM Corp.) was used for statistical analysis be. Continuous data will be presented as mean (SD). Categorical data will be presented as n (%)
- Conditions
- Difficult Airway
- Being tested
- Device intubating Laryngeal Tube Suction Disposable
- Keywords
- iLTS-D, LMA Protector, Fiberoptic intubation
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Device intubating Laryngeal Tube Suction DisposableDevice
Also called Device LMA Protector
Resuscitation in covid 19 patients
| Study group | Role | What they receive |
|---|---|---|
| intubating Laryngeal Tube Suction Disposable | intubating Laryngeal Tube Suction Disposable Airway control Receives: Device: Device intubating Laryngeal Tube Suction Disposable | |
| intubating laryngeal Tube suction Disposable | intubating laryngeal Tube Suction Disposable Receives: Device: Device intubating Laryngeal Tube Suction Disposable |
What is being measured
The primary outcome is the main question the study is designed to answer.
time of success fiberoptic endotracheal intubation
seconds
Measured: 60 seconds
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted6 Nov 2020
- Study start1 Apr 2021 (estimated)
- Primary completion1 Oct 2021 (estimated)
- Study completion31 Dec 2021 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Difficult AirwayStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Prospective
- Enrolment
- 80 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Bnai Zion Medical Center
- Sponsor type
- Other government
- Responsible party
- Principal investigator, LUIS.GAITINI, Bnai Zion Medical Center
- Investigators
- Mostafa Somri, M.D., Study director, Bnai Zion Medical Center Haifa Israel
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT04618926
- Sponsor's protocol ID
- PROTECTOR
- Status last verified
- Feb 2021
- First submitted
- 2 Nov 2020
- Last updated
- 9 Feb 2021
- Results posted
- No
- FDA-regulated drug
- No
- FDA-regulated device
- Yes
Study at a glance
From the registry record, last updated by the sponsor on 9 Feb 2021. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- A Prospective Randomized Study Comparing Fiberoptic Bronchoscope Endotracheal Intubation Between the Intubating Laryngeal Tube Suction and the LMA Protector
- ClinicalTrials.gov ID
- NCT04618926
- Acronym / sponsor ID
- PROTECTOR
- Conditions
- Difficult Airway
- Keywords
- iLTS-D, LMA Protector, Fiberoptic intubation
- Study type
- Observational
- Recruitment status
- Unknown status
- Enrolment
- 80 participants (estimated)
- Lead sponsor
- Bnai Zion Medical CenterOther government
- Study start
- 1 Apr 2021 (estimated)
- Primary completion
- 1 Oct 2021 (estimated)
- Study completion
- 31 Dec 2021 (estimated)
- First posted
- 6 Nov 2020 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Securing the airway is a pivotal skill for anesthesiologists and emergency care providers. Endotracheal intubation (ETI) is considered the gold standard for securing the airway.
When ETI via laryngoscopy has failed, the use of a supraglottic airway device (SGAD) has been recommended. The intubating Laryngeal Tube Suction-Disposable and the LMA Protector are a new step in the evolution of supraglottic airways. Both SGADs are enable to ventilation and oxygenation, but the ventilation channel allow the insertion of an endotracheal tube and the use of fiberoptic bronchoscope. The aim of this study is to compare the time of fiberoptic intubation through the intubating Laryngeal Tube Suction Disposable and the LMA Protector in adult patients.
Detailed description
Detailed Description: Securing the airway is a pivotal skill for anesthesiologist and emergency providers. Endotracheal intubation (ETI) is considered the gold standard for securing the airway. Induction time during anesthesia may sometimes present unexpected difficulties during ETI.
When ETI via laryngoscopy has failed, the use of a supraglottic airway device (SGAD) has been recommended. Previous studies suggested that compare intubation with laryngoscope, SGADs enables rapid and effective airway control. Improved second generation SGADs enable ventilation and oxygenation, but also include a second channel that separates the trachea from the esophagus preventing aspiration. According with the results of the Fourth National Audit Project of the Royal College of Anesthetist will bets and the Difficult Airway Society, the second generation SGADs should be uses instead the first generation.
Some of the second generations of SGADs have a ventilation channel that allow the insertion of an endotracheal tube.
Two of these devices recently introduced in the market are the intubating Laryngeal Tube Suction Disposable (iLTS-D) and the Laryngeal Mask Airway Protector [5, 6] The intubating Laryngeal Tube Suction- Disposable (iLTS-D) (VBM, Germany) is a new updated version of the Laryngeal Tube-Suction Disposable (LTS-D). [5] It has a ventilator channel with a 13.5mm internal diameter, which enables the passage of an Endotracheal Tube (ETT) No 7.5 mm. for fiberoptic guidance. Similarly to the LTS-D, the iLTS-D also has a separate channel for gastric tubes placement up to a size of 18 Fr. The device is latex free, made of PVC, and like the original laryngeal tube (LT), can be inserted blindly.
The iLTS-D comes in one size. According to the depth of insertion, the device will be equivalent to size 4 for patients 175 to 190 cm tall, or size 5 for patients taller than 190 cm.
The LMA Protector™ Airway (Teleflex Ireland) will be a new step in the evolution of supraglottic airways. This is a single use device made mainly of silicone. The LMA Protector is designed to provide an opportunity to insert a tracheal tube of proper size through the device without the need of any special technique. [6] It is a PVC, double- lumen tube. One lumen will be used for ventilation and the others for gastric tube placement.
The ventilation channel has the ability to pass an ETT 7.5 mm with a fiberscope. The LMA Protector will be provide in sizes from 3, 4 and 5. The size 3 will be for patient of weight 30 to 50 Kg, the size 4 to patients of weight from 50 to 70 Kg and the size 5 to patients of weight 70 to 100 Kg.
Unlike the most of the second generation SGAD the LMA Protector possesses a shortand wide-bore preformed airway tube. Thwill be allows passage of wide internal diameter ETTs. It will be currently one of the few second-generation .SADs together with the iLTS-D that can also act as a conduit for endotracheal intubation.
The two SGDs will be inserted blindly with its distal tip positioned in the upper esophagus.
The aim of this be study will be to compare the time of fiberoptic intubation through the intubating Laryngeal Tube Suction Disposable and the LMA Protector in adult patients. The procedures will be performed by anesthesiologist with no previous experience with these two devices.
We hypothesized that the time needed for first-attempt successful fiberoptic-guided intubation with the two novel SADs would not differ by more than 10 s.
MATERIALS AND METHODS The study will obtain the approval of the Bnai Zion Medical Center Clinical Research Ethics Committee and will be obtain the registration from the ClinicalTrials.gov We will recruit patients if they have ≥18 years of age and of American Society of Anesthesiologic (ASA) physical status 1-2. Exclusion criteria included patients who have predicted to a difficult airway, who has any contraindication to the use of an SAD, weight > 90 Kg, aspiration risk and pregnancy woman.
After written informed consent , patients will be assigned, using a computer-generated randomized list, to having their airway intubated fibreopticaly through either an LMA Protector or iLTS-D. Patients will be blinded as to their allocation group.
The intubation will be performed by two experienced anesthesiologist, defined as having more than 10 years of clinical experience since the commencement of specialty and expert with Supraglottic Devices and fiberscope intubation.
All anesthesiologist involved in this study will participate in a standardized educational program and practice on an airway manikin and patients. Anesthesiologist will completed >10 uses on each device prior to the study either in simulators and patients.
The size of the LMA Protector was chosen by the intubating anesthesiologist based on the patient's weight and airway assessment. Size 3 to patient weighs of 30 to 50 Kg and size 4 to patient weight of 50 to 70 Kg. and 5 to patient weight of 70 to 100 Kg. The iLTS-D has only one size with marks in the proximal end of the device with the number 4 or 5 in order to guide the insertion more deep or more superficial according with the height of the patients. Number 4, color red, to adult height of 155-180 cm and number 5, color purple, to adult height of > 180 cm.
For each participant the following data will be recorded preoperatively: age, sex, height, weight, ASA physical status, predictors for difficult airway (Mallampati score, thyromental distance), and type of surgery.
After 3 minutes of pre-oxygenation with 100% oxygen to reach an end-tidal O2 ≥70 %, patients will be given induction agents.
Anesthesia will be induced with up to 2-3 mg/kg propofol, 3mcg/kg fentanyl and maintained with 70% nitrous oxide/30% oxygen and sevofluorane. Neuromuscular blockade will be obtained with rocuronium bromide 0.6 mg/kg.
After complete muscle paralysis (train of four = 0), the allocated SAD will be inserted by the study anesthesiologist according to the manufacturer's instructions.
The time to effective SGAD insertion will be define by the time between the devices was in the level of the lip patients until the CO2 waveform will be observed on the monitor display.
When more than one insertion attempt will be require, the patient will be receive bag-and-mask ventilation between attempts. A fail insertion attempt will be defined as complete withdrawal of the device from the mouth following an unsuccessful placement.
After two attempts the device will be deemed to have fail and the study protocol will be stop.The treating anesthetesiologist will then proceeded with the airway management of their choosing according to the needs of the patient and the surgery.
After achieving satisfactory ventilation via the allocated SAD, fibreoptic-guided tracheal intubation will be start.
A fiberscope (Karl Storz, Tuttlingen, Germany) with an outer diameter of 4.8 mm was used in all fiberoptic-guided procedures. All intubations will be perform with a disposable Endotracheal Tube with a low pressure, high volume cuff (VBM Medizintechnik GmbH, Sulz, Germany) with an internal diameter of 7.5 mm.
The flexible fiberscope will be loaded with the tracheal tube (TT), and advanced 2 cm beyond the TT for guidance. The participant will advance the fiberscope to the end of the SAD and the glottis will be view and assessed.
The scope will be insert into the trachea, the ETT will be railroad into the trachea, and the fibrescope will be then remove. Proper placement of the ETT will be confirm clinically and by the presence of the end tidal CO2 trace. The SAD will be then removed according to the manufacturer's instructions. After this maneuver the position of the ETT relative to the carina will be assessed bronchoscopicaly.
A maximum of two attempts will be s allowed with fibreoptic guided intubation. An alternative airway management plan could be instituted at the criterion by the anesthesiologist if a failed intubation is encountered after two attempts with the allocated device. The time of fiberscope intubation will be defined how the time when the fiberoscope is inserted in the ventilation channel of the SGAD until the presence of the CO2 waveform trace in the display of the monitor.
The primary outcome variable will be the total time to achieve successful fibreoptic intubation through the SADs (time to insertion of the SAD plus time to fibreoptic TI). Secondary variables included the following: SAD insertion time; TT insertion time; intubation success rate, and glottic view according to the Fiber-Optic Scoring System proposed by Brimacombe et al. In order to standardize the assessment of the SGD position (4 = only vocal cords seen; 3 = vocal cords plus posterior epiglottwill be seen; 2 = vocal cords plus anterior epiglottis seen; 1= vocal cords not seen), maneuvers performed to achieve TI (up-down mobilization or side to side mobilization) and Likert scale.
The anesthesiologist will be asked to rate the ease of use of the fiberscope-guided technique on a Likert scale for each technique, using the statement: ''The TT was easily inserted into the trachea'' (1 = strongly agree, 2 = disagree, 3 = neither agree nor disagree, 4 = agree, 5 = strongly agree) (8).
Statistical analysis will be performed. The primary outcome will be time to fiberoptic-guided TI. Based on the pilot study, the investigator expected to obtain a large Cohen's d effect size corresponding to a time difference of at least 10 s, relative to the observed standard deviations (SDs) (9). In order to achieve a statistical significance for such mean time differences when using a repeated-measures procedure with an overall significance level of 0.05 (a = 0.05/3 for each pair with the Bonferroni adjustment) and a power of 0.8, a sample size of 24 would be necessary. The statistical power was calculated using G*Power free, version 3.0.10 (Franz Faul, University of Kiel, Kiel, Germany). A repeated-measures model was used to compare the mean time measurements (SAD insertion time, time to TI, and total time to secure the airway using fiberscope intubation technique among the two devices.
Categorical data were analyzed with nonparametric Friedman's two-way analysis of variance test. If the results were statistically significant at a 5% significance level, the tests were followed by post-hoc multiple compare between each pair of study devices. The paired t-test was used to analyze continuous data, and the Sign test was used to compare two dependent samples of categorical data sets.
According to Bonferroni multiple comparison adjustments, when comparing each pair of devices, p values <0.017 were considered statistical significant. SPSS, version 20 (SPSS Inc., IBM Corp.) was used for statistical analysis be. Continuous data will be presented as mean (SD). Categorical data will be presented as n (%)
Study design
- Observational model
- Cohort
- Time perspective
- Prospective
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| intubating Laryngeal Tube Suction Disposable | – | Device: Device intubating Laryngeal Tube Suction Disposableintubating Laryngeal Tube Suction Disposable Airway control |
| intubating laryngeal Tube suction Disposable | – | Device: Device intubating Laryngeal Tube Suction Disposableintubating laryngeal Tube Suction Disposable |
Who may qualify
- Ages
- 18 to 75 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
- Study population
- We will recruit patients if they are ≥18 years of age and of American Society of Anesthesiologists (ASA) physical status 1-2
Key inclusion criteria (4 listed)
- Patients with normal airway
- weight 50-90kg
- AGE 18-75
- ASA I-II
Key exclusion criteria (4 listed)
- predicted difficult airway
- weight > 90 Kg
- aspiration risk
- pregnancy woman.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Device intubating Laryngeal Tube Suction DisposableAlso: Device LMA ProtectorResuscitation in covid 19 patients | Device | intubating Laryngeal Tube Suction Disposable, intubating laryngeal Tube suction Disposable |
Primary outcome
time of success fiberoptic endotracheal intubation
Time frame: 60 seconds
seconds
Results and safety
Results are not available in the source record.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 9 Feb 2021.
Related trials for Difficult Airway
Not yet recruitingObservational study
Preoperative Frailty and Suboptimal Mask Ventilation in Cardiac Surgery Patients
Frailty, Suboptimal Mask Ventilation
Enrolling by invitation
Pediatric Intubation Simulations With Bougie
Difficult Airway Intubation
Not yet recruiting
Title of Study: Anesthesiologists' Learning Curves for Ultrasound Assessment of Difficult Airway
Airway Ultrasound, Difficult Airway Management
RecruitingObservational study
Airway Ultrasound in Oncologic Maxillofacial Patients
Head and Neck Cancer
Not yet recruitingObservational study
Sniffing Position vs Left Head Rotation (LeHeR) Maneuver for Glottic View During Direct Laryngoscopy
Difficult Intubation, Laryngoscopy
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Mostafa Somri, M.D. study director
Bnai Zion Medical Center Haifa Israel
Questions about this trial
What is this clinical trial studying?
An observational study of Difficult Airway, run by Bnai Zion Medical Center.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 4 inclusion and 4 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: status not confirmed, as of the sponsor's last update on 9 Feb 2021. Status can change between updates, so confirm with the study contact before making plans.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
Results are not available in the source record.
How can a doctor refer a patient or contact the research team?
Contact Luis Gaitini, M.D. (#972506223999, luis.gaitini@gmail.com), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
time of success fiberoptic endotracheal intubation (time frame: 60 seconds). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 9 Feb 2021.